A phase II clinical trial of PRAX-562 to explore the potential in treating a range of rare pediatric developmental and epileptic encephalopathy (DEEs), including SCN2A-DEE, SCN8A-DEE and Tuberous Sclerosis Complex (TSC)
Latest Information Update: 21 Sep 2022
At a glance
- Drugs PRAX-562 (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- 07 Sep 2022 According to a Praxis Precision Medicines media release, this study is anticipated to start before the end of 2022, outside the USA. Topline data expected in 2023.
- 27 Apr 2022 According to a Praxis Precision Medicines media release, this study is expected to initiate in 2H2022.
- 18 Jan 2022 According to a Praxis Precision Medicines media release, the company anticipates reporting topline Auditory Steady-State Response (ASSR) biomarker data in the first half of 2022.